

## **First UK patient treated in ground-breaking Alzheimer's clinical trial**

- Another major milestone for Actinogen Medical, with the first UK patient treated in its Alzheimer's disease trial, XanADu
- Patient enrolled at St Pancras Clinical Research, London
- This is the sixteenth patient to be recruited globally and signals the acceleration of the trial, with 18 research sites open for patient recruitment.
- XanADu now active in all three countries: Australia, the USA and the UK
- Over 50 patients screened for XanADu and first patient enrolled will complete the trial next month.

**Sydney, 16 August 2017: Actinogen Medical (ASX: ACW)** is pleased to announce the enrolment of the first UK patient into XanADu, its study of Xanamem™ in Alzheimer's disease.

This is the sixteenth patient to be enrolled globally across the eighteen research sites currently open. The trial will enrol 174 patients at 20 research sites across Australia, the US and the UK. Actinogen Medical anticipates that the remaining two sites will open for patient recruitment this month. The final patient is expected to be recruited into the trial in Q4 2018.

To-date, over 50 patients have been screened for the study, with at least half expected to progress to enrolment into the trial. In addition, next month the first XanADu patient will complete the study, having reached the end of the 12-week dosing period, and now enters the 4-week follow up phase of the trial.

It is estimated that there are nearly 50 million people with Alzheimer's disease worldwide, increasing to 131 million by 2050<sup>1</sup>. This dramatic increase in the number of people living with Alzheimer's disease makes it critical to find effective new drugs to treat the disease. Progress in the development of Xanamem provides a real opportunity for Actinogen Medical to make a profound difference to Alzheimer's patients and their carers and families worldwide.

The first UK patient was enrolled at St Pancras Clinical Research, in London, UK. The other study sites in the UK open for enrolment are the West London Cognitive Disorders Research and Treatment Unit and the University of Edinburgh Centre for Dementia Prevention.

### **Dr Stuart Ratcliffe, Chief Scientific Officer at St Pancras Clinical Research said:**

*"We are very pleased for our patients to participate in XanADu, a study of a novel new potential treatment for Alzheimer's disease. St Pancras Clinical Research, located in the heart of London, has a catchment area across Greater London of more than 15 million people, and we are committed to undertaking high quality research through new clinical trials to enable enhanced health care in the future. Xanamem offers much promise in a disease area sadly lacking new, effective treatments."*

---

<sup>1</sup> Alzheimer's Disease International (2015) *World Alzheimer Report 2015: The Global Impact of Dementia - an Analysis of Prevalence, Incidence, Cost and Trends*

## **Dr Bill Ketelbey CEO of Actinogen Medical added:**

*“We are delighted to be working with Dr Veronika Horvathova and Dr Stuart Ratcliffe and their team at St Pancras Clinical Research, on the development of Xanamem in Alzheimer’s disease. The XanADu trial represents another important step towards alleviating the burden of Alzheimer’s for millions of people worldwide and we look forward to working together with the St Pancras team in achieving this goal.”*

The trial is registered on [www.clinicaltrials.gov](http://www.clinicaltrials.gov) with the identifier: NCT02727699, where more details on the trial can be found, including the study design, patient eligibility criteria and the locations of the study sites.

## **ENDS**

### **Actinogen Medical**

Dr. Bill Ketelbey

CEO & Managing Director

P: +61 2 8964 7401

E: [bill.ketelbey@actinogen.com.au](mailto:bill.ketelbey@actinogen.com.au)

 @BillKetelbey

### **About Actinogen Medical**

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Actinogen Medical is developing Xanamem a promising new therapy for Alzheimer’s disease, a condition with a multibillion dollar market potential. In the US alone, the cost of managing Alzheimer’s disease is estimated to be US\$250bn, and is set to increase to US\$2tn by 2050, outstripping the treatment costs of all other diseases. Alzheimer’s disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia.

### **About Xanamem™**

Xanamem’s novel mechanism of action sets it apart from other Alzheimer’s treatments. It works by blocking the excess production of cortisol - the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. This enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer’s disease. There is a strong association between chronic stress and excess cortisol that leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer’s disease.

### **About XanADu**

XanADu is a Phase II double-blind, 12-week, randomised, placebo-controlled study to assess the safety, tolerability and efficacy of Xanamem, in patients with mild dementia due to Alzheimer’s disease. XanADu, will enrol 174 patients at 20 research sites across Australia, the UK and the USA. Patient recruitment into XanADu began in Q2 2017 – topline results are expected in Q1 2019. The trial is registered on [www.clinicaltrials.gov](http://www.clinicaltrials.gov) with the identifier: NCT02727699.

Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.